Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 3 · below the Ichimoku cloud · RSI 33 · MACD above its signal · 6% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $207.8K | 0.00% | 87.30K | −28% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CNTB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Xanthopoulos Kleanthis GDirector | Stock Award(Grant) at price 0.00 per share. | 5K | — |
| Jun 29, 2026 | Liu Jean IDirector | Stock Award(Grant) at price 0.00 per share. | 6.7K | — |
| Jun 29, 2026 | Xanthopoulos Kleanthis GDirector | Stock Award(Grant) at price 0.00 per share. | 3.7K | — |
| May 28, 2026 | Huang James ZDirector | Purchase at price 2.48 per share. | 150K | $371.61K |
| Mar 30, 2026 | Huang James ZDirector | Purchase at price 2.62 per share. | 1.16M | $3.04M |
| Mar 30, 2026 | Liu Jean IDirector | Stock Award(Grant) at price 0.00 per share. | 5.1K | — |
| Mar 30, 2026 | Xanthopoulos Kleanthis GDirector | Stock Award(Grant) at price 0.00 per share. | 2.8K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.9 | 2.9 | 6.1 | -5.7 | 0.8 | -4.4 | -15.1 | 8.9 | -50.0 | -17.7 | −67.9% | ||
| 2025 | -29.6 | -6.4 | -39.6 | 49.5 | 2.2 | 16.7 | 106.1 | 2.0 | -26.7 | 13.2 | 64.3 | 0.4 | +104.3% |
| 2024 | -0.8 | 0.9 | 47.5 | -20.1 | 28.8 | -15.1 | -23.0 | 36.8 | -10.0 | -19.4 | -8.6 | 30.2 | +16.9% |
| 2023 | 41.7 | 4.9 | -22.5 | 6.5 | 1.8 | 4.2 | -14.2 | -14.8 | -0.8 | 77.3 | -20.8 | 2.6 | +35.9% |
| 2022 | -10.7 | -14.8 | -23.0 | -32.8 | -60.6 | 8.7 | -6.3 | 71.8 | -7.9 | -32.6 | -16.7 | 19.7 | −83.1% |
| 2021 | -12.1 | -8.5 | 31.3 | 12.7 | 6.6 | 3.2 | -34.6 | -72.5 | 18.4 | −72.2% |
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Buy / hold / sell counts